Cincinnati Children's Hospital Medical Center

Emory University

Karnail Singh

Paul Spearman

Xuemin Chen

Disclosed herein are virus-like particle (VLP)-based monovalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen ('Gag') protein core and a single Ebola glycoprotein selected from either a Zaire (EBOV) glycoprotein or a Sudan (SUDV) glycoprotein. The Ebola glycoprotein may be incorporated into the surface of the spherical Gag core, wherein said VLP-based vaccine presents a single Ebola glycoprotein antigen.

VLP-based monovalent ebola vaccines and methods of making and using same

Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen ('Gag') protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

VLP-based bivalent Ebola vaccines and methods of making and using same

Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group-specific Antigen ('Gag') protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a(EBOV) glycoprotein, and a(SUDV) glycoprotein.

VLP-based bivalent ebola vaccines and methods of making and using same

This disclosure relates to assays for detecting activating antibodies in a sample that are capable of antibody-dependent cell-mediated cytotoxicity. In certain embodiments, this disclosure relates to target cells comprising an antigen on the exterior of the cells and a luciferase inside the cells. In certain embodiments, the antigen is an Ebola-virus glycoprotein. In certain embodiments, this disclosure relates to detecting changes in chemiluminescence of the luciferase as an indication of activating antibodies in a sample capable of cell lysis when mixed with effector cells.

Assays for detecting antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity

Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group&#x2014;specific Antigen ('Gag') protein core and at least two Ebola glycoproteins. The at least two Ebola glycoproteins may be located at the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola glycoprotein antigens. In one aspect, the at least two Ebola glycoproteins are a Zaire (EBOV) glycoprotein, and a Sudan (SUDV) glycoprotein.

Growing community of inventors

Mason, OH, United States of America

Karnail Singh